GSK Reports New Data Showing Arexvy Vaccine Efficacy Against RSV-Associated Lower Respiratory Tract Disease in Adults Aged 60+

According to the Zhitong Finance APP, GlaxoSmithKline (GSK.US) reported new data from the AReSVi-006 Phase III trial, which evaluatedGlaxoSmithKline PLC.Efficacy of the Respiratory Syncytial Virus Vaccine Arexvy in Adults Aged 60 Years and Older Against Lower Respiratory Tract Disease.GlaxoSmithKline PLC.The results show that the vaccine is effective against lower respiratory tract disease and severe disease over two full RSV seasons, including participants with underlying conditions. The company noted that the safety and reactogenicity data are consistent with the preliminary results from the Phase III program.

GlaxoSmithKline PLC.Chief Scientific Officer Tony Wood said, "We look forward to discussing these results with regulatory and vaccine recommendation bodies and gathering more data from the ongoing clinical development program."